Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to improve how it collects data on non-fatal overdoses involving synthetic opioids.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has a longstanding surveillance system in place to collect information on the nature and location of novel drug use, drug markets, and reports alerting us to drug harms experienced. We continue to monitor the threat posed by synthetic opioids, and are working to improve drug surveillance on synthetic opioids through development of an early warning system. The early warning system dashboard will pull together overdose-response data from ambulances, toxicology labs, and other key sources, so we know in near-real time where to target responses.
We know that most overdoses take place when individuals are alone or accompanied by others also using drugs. This means they are largely transitory and hidden events with no opportunity for sampling. A key indicator, therefore, are those who do come into contact with first responders, who are administered the lifesaving opioid reversal drug naloxone, or who are admitted to hospital. Ambulance data represents an opportunity for rapidly identifying local spikes in overdoses and, for this purpose, we are establishing data feeds with ambulance trusts in England on callouts where naloxone has been administered.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department plans to shorten the diagnostic pathway for ovarian cancer by allowing the CA125 blood test and ultrasound to be undertaken at the same time.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department is supporting NHS England in developing Best Practice Timed pathways, to support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard. This standard ensures patients are told they have cancer, or that cancer is ruled out, within 28 days of urgent cancer referral from general practice or screening service.
In March 2023, NHS England published guidance for local health and care systems to implement a timed gynaecological cancer diagnostic pathway, including for ovarian cancer. The gynaecological pathway ensures that at day zero, when presenting with symptoms, an ultrasound and a minimum data set is obtained, which includes a full blood count. For patients with suspected ovarian cancer, the minimum dataset should also include tumour marker CA125, with confirmation of suspicious features of ovarian cancer on ultrasound.
The guidance further ensures that patients with persistent abdominal symptoms, raised CA125, and a normal pelvic scan should be referred through the non-specific symptoms rapid diagnostic centre pathway. Women over 50 years old with elevated CA125 and palpable mass or ascites, or both, or with a previous ultrasound with risk of malignancy, should be referred straight to a computed tomography scan.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of (a) funding and (b) support available for research into non-invasive cancer monitoring technologies.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23 and the NIHR spends more on cancer than any other disease group.
In terms of adequacy of funding, the NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Regarding technologies, the NIHR’s Invention for Innovation (i4i) Programme is a translational research funding scheme aimed at supporting medical devices, such as non-invasive cancer monitoring technologies, and includes in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need. Further information is available at the following link:
https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm
Additionally, in September 2023, the Office for Life Sciences Cancer Mission launched the £12 million NIHR i4i Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call, aiming to support the clinical validation and evaluation of breakthrough technologies that can increase the proportion of cancers that are detected earlier in the disease course and target health inequalities in cancer diagnosis.
The NIHR continues to welcome and encourage funding applications for research into any aspect of human health, including cancer monitoring technologies, and it is worth noting that all applications that were fundable in open competition, have been funded.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the NHS is taking steps with (a) technology developers and (b) academia to help accelerate the introduction of innovative medical solutions.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In February 2023, the Department published the MedTech strategy which outlined how we will work with key stakeholders, including technology developers and academia, to ensure the health and social care system can reliably access safe, effective, and innovative medical technologies. To accelerate the introduction of innovative medical solutions, we are working with stakeholders at pace to implement solutions to streamline and join-up the innovation adoption pathway, from providing clear signals to industry on the innovation we need, to reforming regulation, comparative assessment, and with clearer procurement pathways.
In October 2023, the Government announced £30 million of investment in the Health Tech Adoption and Acceleration Fund. The fund is supporting integrated care systems to invest in the latest technology to help cut waiting lists, speed up diagnosis, and deliver new and improved ways to treat patients. Thanks to this fund, tens of thousands of patients at risk of kidney disease will be able to get tested from the comfort of their own homes. In February 2024, the Government announced eight innovative tech companies who will be supported to bring their devices to market through the Innovative Devices Access Pathway (IDAP). One of the technologies allows chemotherapy patients to self-test at home, using a finger-prick blood test, for neutropenic sepsis. Another is a smartphone app that delivers exercises, cognitive behaviour therapy, and targeted physical activity in a personally customisable format to help patients manage multiple sclerosis.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help encourage innovation in the development of healthcare technology for at home use.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In February 2023, the Department published the MedTech strategy which outlined how we will work with key stakeholders, including technology developers and academia, to ensure the health and social care system can reliably access safe, effective, and innovative medical technologies. To accelerate the introduction of innovative medical solutions, we are working with stakeholders at pace to implement solutions to streamline and join-up the innovation adoption pathway, from providing clear signals to industry on the innovation we need, to reforming regulation, comparative assessment, and with clearer procurement pathways.
In October 2023, the Government announced £30 million of investment in the Health Tech Adoption and Acceleration Fund. The fund is supporting integrated care systems to invest in the latest technology to help cut waiting lists, speed up diagnosis, and deliver new and improved ways to treat patients. Thanks to this fund, tens of thousands of patients at risk of kidney disease will be able to get tested from the comfort of their own homes. In February 2024, the Government announced eight innovative tech companies who will be supported to bring their devices to market through the Innovative Devices Access Pathway (IDAP). One of the technologies allows chemotherapy patients to self-test at home, using a finger-prick blood test, for neutropenic sepsis. Another is a smartphone app that delivers exercises, cognitive behaviour therapy, and targeted physical activity in a personally customisable format to help patients manage multiple sclerosis.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential impact of (a) the breast cancer monitoring device and (b) other innovative medical devices on (i) early cancer detection rates and (ii) patient outcomes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has not yet assessed the potential impact of breast cancer monitoring devices. This technology is at an early stage and further evidence is needed before we can assess whether it could be trialled in medical settings.
Improving the early diagnosis of cancer, including breast cancers, is a priority for the National Health Service. NHS England has an ambition to diagnose 75% of cancers at stage one or two by 2028, which will help tens of thousands of people live for longer. NHS England is working to meet the Faster Diagnosis Standard (FDS) which sets a target of 28 days from urgent referral by a general practitioner or screening programme, to patients being told that they have cancer, or that cancer is ruled out.
In January 2022 the Department provided £10 million of funding for 28 new breast screening units and nearly 60 life-saving upgrades to services in the areas where they are most needed, so more women can be checked for signs of cancer, speeding up diagnosis and treatment.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of breast cancer monitoring devices on global health outcomes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has not yet assessed the potential impact of breast cancer monitoring devices. This technology is at an early stage and further evidence is needed before we can assess whether it could be trialled in medical settings.
Improving the early diagnosis of cancer, including breast cancers, is a priority for the National Health Service. NHS England has an ambition to diagnose 75% of cancers at stage one or two by 2028, which will help tens of thousands of people live for longer. NHS England is working to meet the Faster Diagnosis Standard (FDS) which sets a target of 28 days from urgent referral by a general practitioner or screening programme, to patients being told that they have cancer, or that cancer is ruled out.
In January 2022 the Department provided £10 million of funding for 28 new breast screening units and nearly 60 life-saving upgrades to services in the areas where they are most needed, so more women can be checked for signs of cancer, speeding up diagnosis and treatment.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of ending government support for the UK Recovery programme on the UK's preparedness for future pandemics.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) funded the RECOVERY trial in March 2020, initially for 18 months, before progressively extending the study to March 2024. It was a highly successful trial that, by recruiting patients at a faster rate than any previous trial, was able to rapidly identify the first drugs that reduce COVID-19 mortality. At the end of an NIHR award, including any extensions, researchers can apply through a competitive process for new funding.
The NIHR continues to fund research into infectious diseases, which could be utilised in the event of another pandemic. For example, the NIHR has allocated £2.9 million to Imperial College London and Imperial Healthcare NHS Trust to adapt their COVID-19 trial for severe flu patients. The NIHR is open to applications on any health and care-related topic.
More widely, the UK Biological Security Strategy, published in June 2023, reaffirms our ambition to scale up discovery, development, and manufacturing of therapeutics and vaccines within 100 days of a pandemic being declared. This aligns with our ongoing work to ensure a flexible and capabilities-based approach to pandemic preparedness, which will see emergency planners develop and maintain a generic suite of adaptable response capabilities across the Government. This will enable an approach that can be flexibly deployed to meet the demands of any future pandemic, and support a whole-system response.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has made an assessment of the potential impact of debt collection practices on the (a) mental and (b) physical health of individuals in financial difficulty.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No specific assessment has been made, but we work with HM Treasury to support people with mental ill health facing debt collection. We have been working with HM Treasury and the Money and Pensions Service to promote the mental health Breathing Space scheme, which gives those with mental ill health who are facing financial difficulties, the space to receive debt advice without pressure from creditors or mounting debts. The scheme has protected over 100,000 people who are unable to afford their debt repayments by pausing enforcement action, creditor contact and most interest, fees, and charges for a 60-day period, giving them time to find a debt solution that works for them.
Those receiving mental health crisis treatment can also access a Mental Health Crisis Breathing Space, where the protections last as long as their mental health crisis treatment lasts, plus a further 30 days.
The Government is also delivering a package of cost-of-living support totalling over £104 billion, or £3,700 per household on average, between 2022 to 2025. The Government is continuing to support millions of households most in need, with up to £900 in further cost of living payments in the past year.
Over six million people across the United Kingdom on eligible extra-costs disability benefits have received a £150 Disability Cost of Living Payment, to help with the additional costs they face. More than eight million pensioner households across the UK have received an additional £300 Cost of Living Payment during the winter of 2023/24, paid as a top-up to the winter fuel payment.